
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL is positioned for a constructive fundamental re-rating because Galleri has unusually strong clinical validation, including 99.6% specificity, over 90% Cancer Signal Origin accuracy, a 60% positive-predictive value in PATHFINDER 2, and a 14% reduction in Stage IV diagnoses in NHS-Galleri. The company’s investment case is further strengthened by a large, underpenetrated market opportunity of more than 100 million annual tests in the U.S. at the broadest level, plus potential international expansion and use in nontraditional channels such as concierge medicine, self-insured employers, and telehealth. With FDA approval viewed as increasingly likely and a formal Medicare reimbursement pathway established in February 2026, GRAIL’s extensive dataset and leadership in MCED could support durable long-term adoption and revenue acceleration.
Bears say
GRAIL is burdened by a weak pre-reimbursement commercial ramp, with Q3 screening revenue of about $37.3M and volume near 56,400 missing expectations, while management cut full-year 2026 Galleri screening revenue growth guidance to 17–21% from 22–32%. The company also faces shrinking economics, as adjusted gross margin fell to 42% from 55% a year ago, with a royalty-adjusted level of roughly 35%, and the resumption of the ~7% Illumina royalty in 2027 could further pressure margins if volume growth lags. Beyond these misses, cash-pay demand appears structurally limited by high pricing and weak conversion, and until FDA approval and later reimbursement arrive, the business likely remains trapped in a capital-intensive, cash-burning model with muted visibility on durable scale.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About GRAIL Inc (GRAL) Forecast
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares